Scholarlink

<p>Ki-67 is a nuclear protein expressed during cell proliferation and has been studied as a predictive marker for response to neoadjuvant chemotherapy (NACT) in breast carcinoma. This study evaluates the association between Ki-67 expression levels and pathological response to NACT. A retrospective and prospective observational study was conducted at the Department of Surgical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, from February 2021 to May 2024. A total of 120 biopsy-confirmed breast cancer patients who completed NACT followed by surgery were included. Clinical parameters, tumor characteristics, and response to therapy were analyzed. Statistical significance was set at <i>p</i> &lt; 0.05. The mean patient age was 50.04&#xa0;years (± 10.90). The study cohort included 40.83% HER2 + , 32.50% TNBC, and 26.66% HR + cases. Pathological complete response (pCR) was achieved in 40% of cases. Ki-67 &gt; 30% was significantly associated with higher pCR rates (50% vs. 26%, <i>p</i> &lt; 0.001). There was a significant association between Ki-67 levels and molecular subtypes (<i>p</i> &lt; 0.001). No significant association was observed between Ki-67 levels and clinical response based on PET imaging (<i>p</i> = 0.63). High Ki-67 expression correlates with better chemotherapy response, particularly in TNBC and HER2 + subtypes. However, standardization of Ki-67 assessment is necessary for consistent clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of Ki- 67 as a Predictor of Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

  • 期刊论文

  • 发表日期：

    2025年4月29日

查看全文
  • Muddam Kranthi,
  • R. Ranganath,
  • Rajshekar Shantappa,
  • Monalisa Hui

摘要

Ki-67 is a nuclear protein expressed during cell proliferation and has been studied as a predictive marker for response to neoadjuvant chemotherapy (NACT) in breast carcinoma. This study evaluates the association between Ki-67 expression levels and pathological response to NACT. A retrospective and prospective observational study was conducted at the Department of Surgical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, from February 2021 to May 2024. A total of 120 biopsy-confirmed breast cancer patients who completed NACT followed by surgery were included. Clinical parameters, tumor characteristics, and response to therapy were analyzed. Statistical significance was set at p < 0.05. The mean patient age was 50.04 years (± 10.90). The study cohort included 40.83% HER2 + , 32.50% TNBC, and 26.66% HR + cases. Pathological complete response (pCR) was achieved in 40% of cases. Ki-67 > 30% was significantly associated with higher pCR rates (50% vs. 26%, p < 0.001). There was a significant association between Ki-67 levels and molecular subtypes (p < 0.001). No significant association was observed between Ki-67 levels and clinical response based on PET imaging (p = 0.63). High Ki-67 expression correlates with better chemotherapy response, particularly in TNBC and HER2 + subtypes. However, standardization of Ki-67 assessment is necessary for consistent clinical application.